SCHEMBL3479741

SCHEMBL3479741

CN1CCN(c2ccccc2)c2ccc(-n3ncccc3=O)cc2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.42
KCNH2 Q12809 1/20 0.42
SCN9A Q15858 1/20 0.40
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
DRD3 P35462 1/20 0.34
HTR6 P50406 1/20 0.34
KHK P50053 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479649 0.89 HRH3 (0.47) HRH3KCNH2SCN9ASMN1; SMN2LMNA
SCHEMBL3479590 0.88 HRH3 (0.40) HRH3KCNH2SCN9ASMN1; SMN2CA12
SCHEMBL3479734 0.87 HRH3 (0.39) HRH3KCNH2SCN9AKMT2ACA12
SCHEMBL3231196 0.87 SLC6A2 (0.47) HRH3KCNH2SCN9ALMNASLC6A2
SCHEMBL3235782 0.84 HRH3 (0.39) HRH3KCNH2SCN9ASMN1; SMN2POLB
SCHEMBL3479776 0.83 HRH3 (0.40) HRH3KCNH2SCN9ASMN1; SMN2POLB
SCHEMBL3479708 0.82 HRH3 (0.41) HRH3KCNH2SCN9ASMN1; SMN2LMNA
SCHEMBL3227525 0.82 HRH3 (0.41) HRH3KCNH2SCN9ALMNACA12
SCHEMBL3222466 0.82 HRH3 (0.39) HRH3KCNH2SCN9ACA12CA1
SCHEMBL3479641 0.81 HRH4 (0.44) SCN9AKMT2ASMN1; SMN2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D HRH3 84/4885KCNH2 537/4885SCN9A 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.